Miquel Àngel Pavón holds a Biology degree (Universitat utònoma de Barcelona, 2002) and a PhD in Biomedicine (Universitat de Barcelona, 2009).

As a graduate student (2002-2003), he joined to the Hepatitis C research group at the Hospital Clinic the Barcelona and collaborated with a study to analyse the role of HCV genome variability on the development of acute, chronic disease or cancer. From 2003 to 2009 was trained as a pre-doctoral student at the Oncogenesis and Antitumor Drugs Group at Sant Pau Biomedical Research Institute (IIB-Sant Pau). His PhD project was focused on identifying new gene expression signatures and molecular pathways associated with treatment response and the clinical outcome in patients with head and neck cancer. During his period as a postdoctoral researcher, he focused his research on the development of in vitro and in vivo models for studying the head and neck cancer metastatic dissemination

In May 2016, MA Pavón joined the Cancer Epidemiology Research Program (PREC) in the Catalan Institute of Oncology (ICO) as a coordinator of the Infection and Cancer Laboratory (INCALAB), where he has extended his research to all neoplasm associated with Human Papillomavirus (HPV) infection. Beyond coordinating the laboratory's diagnostic and screening activity, he leads several research studies focused on identifying new molecular markers associated with HPV infection persistence and cancer progression. In 2017 he conducted a short stage as a visiting researcher at the National Cancer Institute (NCI, EEUU). He is currently leading a study aimed to identify new Human papillomavirus 16 genetic variants associated with invasive progression in vulvar cancer (VPH16-INVASIV PI17/00123). He recently opened a new research line to analyse if the vaccination is a suitable strategy to limit infectivity of body fluids from HPV positive women (RIFT1 / 2 MISP; HPV-VIOLIN PI20 / 018) as a potential strategy to limit HPV transmission

He collaborates as a researcher in the CIBER-ESP group of the UNIC and as a secretary of the functional diagnosis unit of the human papillomavirus (UD-VPH) that joins all the departments and clinicians involved in screening, diagnosis and treatment of HPV-associated neoplasms in the environment of the ICO, Bellvitge’s Hospital and the associated centres of the southern metropolitan area